Posts By: FFB Canada

RPE65 Gene Therapy Trials for Leber Congenital Amaurosis Update

May 27th, 2014 by FFB Canada

At the Association of Vision Research and Ophthalmology meeting earlier this month, Dr. Jean Bennett delivered a keynote address focusing on gene therapies. Dr. Bennett has been the principal investigator for some of the trials of gene therapy for Leber congenital amaurosis (LCA) type 2 (caused by mutations in RPE65). It is a series of…

Read More

Potential Therapy to Slow Retinal Vision Loss

May 8th, 2014 by FFB Canada

Today, at the ARVO meeting, a Canadian team led by Dr. Uri Saragovi presented details of a potential therapy for retinitis pigmentosa and other retinal degenerative diseases. The therapy is based on GDNF (Glial cell-line derived neurotrophic factor) a substance naturally found in the body. The therapy is not ready for human testing yet, but the early evidence…

Read More

Valproic Acid as a Treatment for Retinitis Pigmentosa

May 7th, 2014 by FFB Canada

Clinical trials of valproic acid for the treatment of retinitis pigmentosa began in both the USA and Korea in late 2011. As well, a smaller shorter open-label trial was begun in Japan. Although the two larger trials have not yet reported, results of the small 30-person Japanese trial were presented at ARVO. The trial did…

Read More

Genetic Testing & Retinitis Pigmentosa

May 6th, 2014 by FFB Canada

For the past 20 years, scientists have been discovering the genetic mutations that underlie inherited retinal diseases like retinitis pigmentosa. As the technology to evaluate genetic mutations becomes more readily available, scientists are able to look at and evaluate samples from a large number of people. Finding genes and mutations are important, as this endeavour…

Read More

The Long-Term Treatment of Wet AMD

May 6th, 2014 by FFB Canada

At this year’s ARVO meeting, multiple presentations examine what we are learning about the treatment of wet age-related macular degeneration, now that therapeutic injections of anti-VEGF drugs are in wide-spread use. Three drugs are commonly used: Lucentis (approved in Canada for several years), Eyelea (approved in Canada last fall) and Avastin (a cancer drug, which…

Read More

One Year Results of Choroideremia Gene Therapy Trial

May 4th, 2014 by FFB Canada

In January, follow-up results from the first six months of the British choroideremia gene therapy trial were published. At the Association for Vision Research and Ophthalmology meeting today, the team led by Dr. Robert MacLaren and Dr. Miguel Seabra presented the outcomes for the first year of the study. Once again, Dr. MacLaren and colleagues…

Read More

Trial of Treatment to Slow Retinitis Pigmentosa Vision Loss Begins in Italy

April 15th, 2014 by FFB Canada

An eye drop designed to slow the advance of retinitis pigmentosa has just begun testing in human clinical trials. The drug contains recombinant human Nerve Growth Factor (rhNGF), a molecule that investigators believe will help slow the death of photoreceptors, potentially protecting and extending vision. The trial will involve 50 people treated at five clinical…

Read More

Patty’s Story: Real Life Research Results

April 14th, 2014 by FFB Canada

At the age of 58, Patty Gill noticed a dark cloud appear in the vision of one of her eyes. She didn’t think much of it at first, but after a number of visits to her eye doctor she learned she had wet age-related macular degeneration (AMD) – the most severe form of a blinding…

Read More

Geneticist’s Sight-Saving Contributions Recognized

March 31st, 2014 by FFB Canada

Dr. Jane Green’s research has improved life for thousands of people with inherited retinal diseases. Her pioneering research, supported by the Foundation Fighting Blindness, helped give many people a clear diagnosis and understanding of their disease, which is the first step in learning how to cope with it and plan for the future. Early this month,…

Read More

A Link Between Exercise & Vision Health

March 25th, 2014 by FFB Canada

Now that spring finally seems like a possibility, there is another good reason to get out an exercise. A new study from scientists in Atlanta is beginning to explain how exercise can help protect against age-related macular degeneration (AMD) – and perhaps other retinal diseases as well. Like much research, this study was done in mice….

Read More